Dr. Chin is the Bertarelli Professor of Translational Medical Science and Professor of Medicine Emeritus at Harvard Medical School (HMS). Dr. Chin was formerly Executive Vice President for Science and Regulatory Advocacy and Chief Medical Officer (CMO) at Pharmaceutical Research and Manufacturers of America (PhRMA) where he led PhRMA’s continuing efforts in science and regulatory advocacy in the drug discovery and development ecosystem working closely with the leadership of FDA & NIH. Prior to PhRMA, he was the Executive Dean for Research at HMS. Before that, he was at Eli Lilly and Company last as Senior Vice President for Discovery Research and Clinical Investigation where he oversaw the development of >100 drug candidates. Currently, he is a scientific advisor and board director for a number of biotech companies.

Dr. Chin is a Harvard-trained endocrinologist and longstanding faculty member. His career is highlighted by leadership in molecular endocrinology and translational science and medicine during his 25 years on the Harvard Medical School faculty. During this time, Dr Chin was Chief of the Genetics Division in the Department of Medicine at Brigham and Women’s Hospital, a Howard Hughes Medical Institute Investigator and Professor of Medicine, and Obstetrics, Gynecology and Reproductive Medicine at HMS. He has been honored with numerous awards for research, mentorship, and leadership.

Over 40 years, Dr Chin has had roles to advise and otherwise help Singapore in developing its current innovation ecosystem with a focus on biotechnology. He is an active Board Member of the Agency of Science Technology and Research
(A-STAR) in Singapore. Dr. Chin received his A.B. in Chemistry from Columbia University and his M.D. from Harvard Medical School. In 2023, Dr. Chin was awarded an honorary citizenship in recognition of his contributions to developing the Singapore innovation ecosystem.